Milestone Pharmaceuticals Inc - fluxo de caixa (NASDAQ:MIST) | MetaTrader

Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas

Cash from operating activities -50.73 M-33.22 M-52.47 M-46.42 M-28.85 M-49.04 M -49.04 M Cash from investing activities -70 M70 M-57.12 M4.76 M8.28 M11.25 M 11.25 M Cash from financing activities 73.22 M5.05 M3.09 M47.79 M32.12 M85.53 M 85.53 M Free cash flow -50.73 M-33.22 M-52.74 M-46.54 M-28.88 M-49.34 M -49.34 M

Notícias

Milestone Pharmaceuticals planeja estudo de registro de TPSV no mundo real

Raymond James inicia cobertura da Milestone Pharmaceuticals com recomendação de compra forte

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals atinge previsão de LPA, mas ação cai

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)

Sistema de spray nasal da Aptar entregará novo tratamento aprovado para TPSV

Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher (MIST)